[1] 崔云惠, 朱绍成, 李泓享, 等. IVIM对上皮源性卵巢肿瘤良恶性鉴别的诊断价值及与ki67表达的相关性[J]. 磁共振成像, 2020,11(1):55-59. [2] 郑凤英, 靳国荣, 刘亚非, 等. 糖类抗原199、癌胚抗原和甲胎蛋白联合检测诊断卵巢癌的价值[J]. 海南医学, 2018,29(1):74-76. [3] Fakhar H B, Rezaie-Tavirani M, Zali H, et al. Comparison of serum human epididymis protein (HE4), carbohydrate antigen 125(CA125) and risk of ovarian malignancy algorithm (ROMA) as markers in ovarian cancer:a systematic review and a meta-analysis[J]. Indian Journal of Gynecologic Onco-logy, 2018,16(1):10-11. [4] 高飞, 周辉, 董江宁, 等. 体素内不相干运动扩散加权成像对良恶性骨肿瘤的鉴别诊断价值[J]. 临床放射学杂志, 2019,38(4):695-699. [5] 莫树群, 曹惠霞, 韩立新, 等. 体素内不相干运动扩散加权成像对前列腺癌的诊断价值[J]. 放射学实践, 2018,33(6):603-607. [6] Abramowicz J S, George C, Dirk T. Ovarian mass-differentiating benign from malignant. Why the international ovarian tumour analysis rules should be implemented in Australasia[J]. Australasian Journal of Ultrasound in Medicine, 2018,21(3):121-124. [7] Hao X Q, Liu G, Hai F Y, et al. Differentiation between orbital malignant and benign tumors using intravoxel incoherent motion diffusion-weighted imaging:correlation with dynamic contrast-enhanced magnetic resonance imaging[J]. Medicine, 2019,98(12):14897-14898. [8] 钱洛丹, 吴慧, 高阳, 等. DWI不同模型在卵巢肿瘤诊断中的应用[J]. 磁共振成像, 2019,10(10):797-800. [9] 任继鹏, 孟楠, 周凤梅, 等.多模型体素不相干运动联合血清CA125对卵巢肿瘤的诊断价值[J]. 中国CT和MRI杂志, 2018,16(3):79-82. [10] 魏毅, 高菲菲, 黄子星, 等. 基于全体素测量磁共振扩散加权成像单指数模型及体素内不相干运动模型参数对肝癌术前病理分级诊断价值[J]. 中华医学杂志, 2018,98(31):2460-2465. [11] 于庆, 靳海英. 基于IVIM的MR扩散加权成像(DWI)对卵巢癌分型的诊断价值[J]. 中国CT和MRI杂志, 2020,18(6):124-126. [12] Shi H, Quan X, Liang W, et al. Evaluation of placental perfusion based on intravoxel incoherent motion diffusion weighted imaging (IVIM-DWI) and its predictive value for late-onset fetal growth restriction[J]. Geburtshilfe Und Frauenheilkunde, 2019,79(4):396-401. [13] Wei Z, Wenguang L, Huaping L, et al. Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging[J]. PloS One, 2018,13(5):197488-197489. [14] Migda M, Bartosz M, Migda M S, et al. Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment[J]. Journal of Ovarian Research, 2018,11(1):92-93. [15] Moro F, Pasciuto T, Djokovic D, et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses[J]. Ultrasound in Obstetrics & Gynecology, 2018,53(1):116-123. [16] Asya P, Jalid S, Desislava D, et al. Preoperative CA-125 value as a predictive factor for postoperative outcome in first relapse of platinum-sensitive serous ovarian cancer[J]. Anticancer Research, 2018,38(8):4865-4870. [17] Lena S D, Lavie O, Auslander R. CA19-9 in Evaluation of adnexal mass:retrospective cohort analysis and review of the literature[J]. International Journal of Biological Markers, 2018,30(3):333-340. [18] Gao P, Liu Y, Shi C, et al. Performing IVIM-DWI using the multifunctional nanosystem for the evaluation of the antitumor microcirculation changes[J]. Magnetic Resonance Materials in Physics, Biology and Medicine, 2020,33(4):517-526. [19] Sungsik K, Soochi K, Jinhyun K, et al. Evaluating tumor evolution via genomic profiling of individual tumor spheroids in a malignant ascites from a patient with ovarian cancer using a laser-aided cell isolation technique[J]. Scientific Reports, 2018,8(1):12724-12725. [20] Yao S, Li L, Su X T, et al. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment:in vitro and in vivo[J]. Journal of Experimental & Clinical Cancer Research, 2018,37(1):29-30. |